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trials mixed these types in different (and even unstated) propor-
tions. Some (n = 12) required sinus rhythm for various durations
at randomization, increasing the chance of success; 4 ignored
early recurrences or allowed for recardioversion, while 16
counted every recurrence. In addition, methods used to detect
recurrence varied from ECG conﬁrmation at regularly scheduled
visits to much more sensitive trans-telephonic monitoring (n =
11), which was employed in differing ways. Furthermore, efﬁ-
cacy endpoints were affected by biased termination of follow-up,
as treatment withdrawal due to side effects leads to less detec-
tion of recurrence. Nevertheless, a published meta-analysis
ignored these differences, citing similar recurrence rates in
control groups and chi-squared tests that did not detect statisti-
cal heterogeneity. In our opinion, this does not adequately
address heterogeneity in study designs, and the resulting esti-
mates are unsuitable for economic modeling. CONCLUSION:
Strict adherence to frequentist views can lead to inappropriate
pooling of trial data and erroneous inputs for economic models.
A Bayesian perspective provides a more correct view of the
intractable study design differences.
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OBJECTIVES: Educating hypertensive patients in blood pressure
management can improve clinical outcomes. The BPSZ Program
is a nationwide educational program which provides participants
with tailored educational materials in addition to a complimen-
tary trial of one of three different antihypertensive medications.
The BPSZ-BLISS study is a naturalistic study to evaluate the
effectiveness of the BPSZ program by utilizing a sub-set of the
Program participants and measuring the following: blood pres-
sure (BP) control, compliance, persistence and treatment satis-
faction. METHODS: 20,000 MDs enrolled in the BPSZ Success
Zone program were invited to participate in the study. Using an
Interactive Voice Response System (IVRS), MDs report BP and
other data at the enrollment visit and at every usual care visit up
to 12 +/−2 months; subjects self-report BPs, persistence, compli-
ance and treatment satisfaction at 3, 6 and 12 months post BPSZ
enrollment. MDs and subjects are supported by call center rep-
resentatives as needed. In addition to BPSZ program enrollment
medication, MDs prescribe anti-hypertensive medications and
schedule visits as per usual care. The General Electric Health care
database will be used as an external referent to facilitate inter-
pretation of study outcomes. RESULTS: After 12 months, 2,000
IRB approved MDs have enrolled over 10,000 subjects (48%
male; mean age 56 years; 26% newly diagnosed); 97% of MDs,
and 75% of subjects successfully entered IVRS enrollment data.
Automated IVRS validations have successfully maintained
cohort integrity and data quality (less than 5% error on key
study variables). MD and patient enrollment will continue until
April 2007; study completion is scheduled for mid 2008. CON-
CLUSION: MD and patient enrollment, and the acquisition of
outcomes data in a nationwide health education program require
innovative design and automated data management and quality
control methodologies. Strengths and weaknesses of the BPSZ-
BLISS study design can help inform similar health education
program evaluation initiatives.
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OBJECTIVES: To compare mobile phone messaging and postal
reminders as means of increasing the attendance rate during the
ﬁrst 24 weeks of lipid-lowering therapy among hyperlipidemic
patients in primary care. METHODS: The study was a ran-
domized controlled trial of 918 patients from 19 family practice
clinics conducted between February 2003 and June 2005.
Patients were randomly assigned to receive mobile phone
message reminders, postal reminders, and control strategies. To
ascertain attendance rates, patients were regularly followed up
12 to 24 weeks after their treatment. Reminders were sent on
average at 16 weeks. The primary measure was the attendance
rate at 24 weeks. A secondary outcome was identifying the direct
cost and beneﬁts of each reminder type. RESULTS: Overall
attendance rate was 74.1%. This differed between groups, with
76.1% attendance for the mobile phone messaging group,
73.5% for postal reminders, and 72.4% for the control group.
According to a multivariate analysis, the mobile phone messag-
ing group had a signiﬁcantly higher attendance rate (OR 1.48,
95% CI: 1.01–2.16) than the control group, but the postal
reminder group (OR 1.15, 95% CI: 0.79–1.69) did not. More-
over, for one additional visit, the marginal cost of mobile phone
messaging (USD 3.1) was much lower than that of postal
reminders (USD 47.0). CONCLUSION: Mobile phone messag-
ing is a more cost-effective method to increase the attendance
rate at 24 weeks after lipid lowering therapy among hyperlipi-
demic patients.
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OBJECTIVES: To evaluate the ability of interactive voice recog-
nition (IVR) technology to improve statin adherence in a cohort
of new start patents. METHODS: Plan members were identiﬁed
based on the existence of a ﬁlled prescription for statin therapy
between May 1, 2005 and December 1, 2005 and randomized
to intervention or control group. Statin prescription claims were
evaluated through June 25, 2006 when study analysis was com-
pleted. Subjects had to be 18 years or older, continuously
enrolled in the health plan for 2 years, and new users of statin
therapy. Members enrolled in any other plan-sponsored IVR ini-
tiative were excluded from this analysis. The intervention group
received three automated phone calls; call one provided disease
state education, call two was a reﬁll reminder, and call three
addressed the importance of physician follow up. The program
provided customized interaction based on patient response,
primary vs. secondary prevention, and reﬁll behavior. Persistence
